Paolo Tarantino, Research Fellow Dana-Farber Cancer Institute and Harvard Medical School, shared a post on LinkedIn:
“Only few days to ASCO26.
For breast oncologists, this edition will deliver a new promising biomarker to spare unnecessary chemotherapy, informative updates from practice-changing trials across subtypes, and major innovations coming from China.
See you in Chicago next week!”
Other articles featuring Paolo Tarantino on OncoDaily.